Ferric Maltol Of WBCIL: Optimized Absorption, Minimal Toxicity, And Sustainable Production For Chron

Citation: Dr. Poulami Gupta Banerjee || Dr. Atanuka Paul || Dr. Argha Chakraborty || Dr. Abhijet Porel || Abir Kumar PalIOSR Journal Of Pharmacy And Biological Sciences (IOSR-JPBS) e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 20, Issue 1 Ser. 2 (Jan. – Feb. 2024), PP 42-51 www.Iosrjournals.Org. https://www.iosrjournals.org/iosr-jpbs/papers/Vol20-issue1/Ser-2/H2001024251.pdf

Abstract: Iron deficiency is the most common cause of anaemia globally. It is frequently reported in patients with underlying inflammatory conditions, such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). The treatment goals are to treat the underlying cause, limit further blood loss or malabsorption, avoid blood transfusions in haemodynamically stable patients, relieve symptoms, and improve quality of life [1]. Ferric maltol is a new oral iron replacement therapy designed to optimize iron absorption while reducing the gastrointestinal adverse events associated with unabsorbed free iron.